2025 Nobel Prize in medicine goes to immune tolerance researchers, not GLP-1 drugs
The 2025 medicine Nobel went to immune-tolerance research, not GLP-1 science; U.S. patients' drug approvals, prices and coverage are unaffected.
On Oct. 6, the Nobel Assembly at Karolinska Institutet awarded the 2025 Nobel Prize in Physiology or Medicine to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for discoveries about peripheral immune tolerance, the system that keeps the immune system from attacking the body's own organs [1]. The award went to immunology, not to the GLP-1 science behind the diabetes and obesity drugs.
The prize recognizes work that began in 1995, when Shimon Sakaguchi identified a previously unknown class of immune cells that protect against autoimmune disease [1]. At the time, most researchers believed tolerance developed only when potentially harmful immune cells were eliminated in the thymus, a process called central tolerance [1]. "Their discoveries have been decisive for our understanding of how the immune system functions and why we do not all develop serious autoimmune diseases," said Olle Kämpe, chair of the Nobel Committee [1].
In 2001, Mary Brunkow and Fred Ramsdell found the reason a particular mouse strain was especially vulnerable to autoimmune disease: a mutation in a gene they named Foxp3 [1]. They also showed that mutations in the human version of that gene cause a serious autoimmune disease, IPEX [1]. Two years later, Sakaguchi showed that Foxp3 governs the development of the cells he had found in 1995, now known as regulatory T cells, which monitor other immune cells and make the body tolerate its own tissue [1].
The three laureates share the prize amount of 11 million Swedish kronor equally [1]. Brunkow, born 1961, is a senior program manager at the Institute for Systems Biology in Seattle; Ramsdell, born 1960, is a scientific advisor at Sonoma Biotherapeutics in San Francisco; Sakaguchi, born 1951, is a distinguished professor at Osaka University's Immunology Frontier Research Center in Japan [1]. The Nobel Assembly, which awards the medicine prize, is made up of 50 professors at Karolinska Institutet, and the prize has been given since 1901 [1].
The announcement named no GLP-1 researcher, and no GLP-1 or obesity drug was recognized. The discoveries it honored launched the field of peripheral tolerance, which the assembly says has spurred development of treatments for cancer and autoimmune diseases and may lead to more successful transplantations, with several of those treatments now in clinical trials [1].
Why it matters for patients
The Nobel is a scientific honor, not a regulatory or insurance decision. It does not change what semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or orforglipron (Foundayo) is approved for, what it costs, or whether a health plan covers it.
For people with autoimmune disease, cancer or an organ transplant, the honored research is the basis of experimental treatments, not of anything available today. The assembly says several treatments built on this work are in clinical trials [1], but it gave no drug names, no trial phases and no results.
What has not been disclosed
The announcement did not identify which peripheral tolerance treatments are in trials, when results might be reported, or which companies are developing them [1]. It also does not say whether GLP-1 research was nominated or considered for this year's medicine prize [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.